Previous 10 | Next 10 |
2023-03-28 13:22:51 ET Summary Since my previous bullish article on ASRT stock, it has gained 68.54% and continues thriving. Time to update my thesis. Thanks to the addition of 2 new drugs to its sales structure, which now account for over 8% of total sales, ASRT increased it...
2023-03-28 12:31:24 ET Summary Assertio Holdings, Inc. has impressive growth rates and an attractive valuation. The company's involvement with an opioid in the past may explain the low valuation. Assertio Holdings has a low forward P/E ratio of 11.48x and a trailing twelve-mon...
2023-03-28 06:00:00 ET Summary Companies with strong profitability tend to have more stable earnings and cash flows, which can make them more resilient to market volatility. This article focuses on stocks with a proven track record of profitability. High-quality stocks come in all...
2023-03-09 10:01:05 ET Gainers: Ocean Biomedical OCEA +57% . Avenue Therapeutics ( ATXI ) +21% . Unicycive Therapeutics ( UNCY ) +19% . Assertio ( ASRT ) +12% . Immuneering ( IMRX ) +11% . Losers: InVivo Therapeutics NVIV ...
2023-03-08 21:42:17 ET Assertio Holdings, Inc. (ASRT) Q4 2022 Earnings Conference Call March 08, 2023 04:30 PM ET Company Participants Matt Kreps - Darrow Associates, Investor Relations Dan Peisert - President & Chief Executive Officer Paul Schwichtenberg - S...
2023-03-08 20:28:25 ET The following slide deck was published by Assertio Holdings, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Assertio Holdings, Inc. 2022 Q4 - Results - Earnings Call Presentation
2023-03-08 16:37:50 ET Assertio Holdings ( NASDAQ: ASRT ) is up 1% in after-hours trading after posting Q4 2022 earnings that beat on the top and bottom lines. For 2023, the company is also projecting net product revenues, on GAAP basis, of $150M-$160M. The consensus r...
2023-03-08 16:04:00 ET Assertio Therapeutics press release ( NASDAQ: ASRT ): Q4 Non-GAAP EPS of $0.32 beats by $0.12 . Revenue of $50.35M (+51.1% Y/Y) beats by $2.91M . Adjusted EBITDA increased to $33.4 million, from $17.8 million. The Company’s gro...
Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA Increases to $101.6 Million Cash Flows from Operations Was $26.7 Million for the Fourth Quart...
LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced the appointment of Howard J. Franklin, MD, as Se...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...
LAKE FOREST, Ill., May 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that its Board of...